Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Correction: Cost-effectiveness...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Correction: Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.

Correction: Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.

[This corrects the article DOI: 10.1371/journal.pone.0278460.].

Bibliographic Details
Main Authors: Florian Schwarz, Habibollah Arefian, Michael Hartmann, Ingo Runnebaum
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0303776&type=printable
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0303776&type=printable

Similar Items

  • Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.
    by: Florian Schwarz, et al.
    Published: (2022-01-01)
  • Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
    by: Florian Schwarz, et al.
    Published: (2022-01-01)
  • Correction: Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
    Published: (2024-01-01)
  • Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
    by: Antonio Olry de Labry Lima, et al.
    Published: (2021-08-01)
  • RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
    by: Denise Zou, et al.
    Published: (2021-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs